Category: LensAR Inc.
The FDA grants 510(k) clearance to LensAR's laser surgery system for a type of incision made during cataract surgeries.
The laser cataract surgery market has another player, now that the FDA's cleared its laser surgery device for another type of incision used during cataract surgery procedures.
LensAR said it won 510(k) clearance from the FDA for its laser cataract surgery device for arcuate incisions to the edge of the cornea.
The FDA OKs LensAR's laser system for executing corneal incisions, giving the system full indications for all the critical components of laser cataract surgery.
Orlando, Fla.-based LensAR won additional FDA clearance for its next-generation LensAR laser system, gaining indication for performing corneal incisions during cataract surgery.
With the latest regulatory win the LensAR system is cleared for all critical aspects of laser cataract surgery, including lens fragmentation, anterior capsulotomy and corneal incisions, according to the press release.
Angel Medical Systems raises nearly $28 million for its ischemia monitoring device, designed to give early warning of an incipient heart attack.
Angel Medical Systems said it's closed a funding round worth $28 million for its AngelMed Guardian implant, designed to detect the early heart problems that can lead to heart attacks and alert patients to seek medical care.
The round included existing backers and a new contribution from SOAM Angel Partners, which added principal Dr. Victor Whitman to Angel Medical's board, according to a press release.
Teleflex appoints former TomoTherapy finance chief Thomas Powell to be its new CFO following the departure of Richard Meier, who was terminated for undisclosed reasons.
Teleflex (NYSE:TFX) named Thomas Powell CFO effective March 9, replacing Richard Meier, who was ousted the same day.
Powell joined the Limerick, Pa.-based device maker last year as senior vice president of global finance, according to regulatory filings, prior to which he was CFO of TomoTherapy, which was subsequently sold to Accuray (NSDQ:ARAY).
The venture capital industry backs a push for passage of a bill that would make it easier for small companies to go public; also, VCs shift focus from high-tech med-tech; S&P affirms Boston Scientific's BBB rating; Allezoe CEO gets threats over PR policy; angels in America spent more on device makers last year; Flextronics buys Stellar Microelectronics; Philips Healthcare wins U.S. Army training contract; OTC exchange lists Avita Medical; iCad wins NASDAQ reprieve; Premier issues new GPO deals; plus, a Funding Roundup and analysts' ups and downs.
The National Venture Capital Assn. is spearheading a drive to get a bill through the U.S. Senate that would make it easier for small companies to raise money by going public.
The "IPO On Ramp" measure would ease the regulatory requirements for IPOs and temporarily reduce the reporting burdens imposed by the Sarbanes-Oxley Act.
NuVasive completes its $80 million buyout of Impulse Monitoring; also, Bio-Rad buys QuantaLife for $162M; Topcon puts some coin in LensAR; ConvaTec's AmCare unit buys Farmhurst Medical; Cyberonics gets strategic with ImThera Medical; AeroScout buys Sentient Health; Welch Allyn closes Trimline deal; Precision Engineered Products buys Boston Endo-Surgical; and Aptiv Solutions buys fellow CRO SRA Global Clinical Development.
NuVasive (NSDQ:NUVA) closed its $80 million pickup of Impulse Monitoring Inc. last week, according to a filing with the federal Securities & Exchange Commission.
The deal, which closed Oct. 7, saw IMI's shareholders receive nearly $40.5 million in cash and more than 2.3 million shares of NuVasive common stock with an aggregate value of about $40.5 million (per NUVA's Oct. 6 closing share price of $17.32).